Supportive Care

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen.

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment regimens, locations, and more.

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age of immunotherapy.

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for patients with cancer.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

In the phase 3 SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide as second-line therapy for high-risk essential thrombocythemia.

Cassie A. Gray, MS, RN, OCN, CHPN, explains how early palliative care integration benefits patients with advanced cancer.

Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, shared a review of supportive oncology practices at the 2025 School of Nursing Oncology.

The addition of atezolizumab to chemoradiation led to meaningful improvements to quality of life for patients with small cell lung cancer.

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head and neck cancers.

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses precision supportive care and tailored survivorship strategies in an ONN interview.

At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.

Benjamin Besse, MD, PhD, shares AE management strategies for amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.

Read an advanced practice nurse's tips for treating patients with endometrial cancer with durvalumab.

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Familiarity with each component of antibody-drug conjugates helps nurses and APPs deliver proactive adverse event management to patients with cancer.

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.

Understanding which patients may benefit from CLDN6-targeting immunotherapy and recognizing potential adverse effects is essential for oncology nurses.

The role of nurses and APPs is crucial to ensuring patients with cancer can receive newer therapies, shares David A. Braun, MD, PhD.

Survey results show patients may overestimate dermatologic AEs from anti-cancer therapies, raising concerns for treatment adherence.

Nurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.

Ronald Bleday, MD, discusses how nurses support a step-wise model to minimize opioid use after colorectal surgery while ensuring safe pain control.

Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.